Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections
JAMA
.
2017 Sep 19;318(11):1003-1004.
doi: 10.1001/jama.2017.11502.
Authors
Jonathan Kimmelman
1
,
Benjamin Carlisle
1
,
Mithat Gönen
2
Affiliations
1
Studies of Translation, Ethics and Medicine (STREAM), Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada.
2
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
PMID:
28837722
DOI:
10.1001/jama.2017.11502
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
Clinical Trials as Topic*
Drug Discovery*
Health Policy*
Humans
Patient Safety
United States
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States